

Dear Elise,

Thank you for the opportunity to comment on your important analysis. The Michael J. Fox Foundation for Parkinson's Research (MJFF) is dedicated to advancing scientific breakthroughs and engaging partners in that pursuit, both of which require research transparency and access.

We fund a portfolio of activities across the preclinical, translational and clinical stages, applying transparency and sharing principles to all of them. The clinical part of our portfolio includes our flagship effort, the observational [Parkinson's Progression Markers Initiative](#). As study sponsor, MJFF has made available all data in real-time, as well as protocol documents and publications. The program also includes making biosamples and cell lines broadly available. In addition, MJFF partners with others in the space for Accelerating Medicines Partnership Parkinson's Disease (AMP PD), which makes clinical, biological and genetic data available to the community.

For parkinsonian human studies (funded by our Foundation and by others), MJFF has developed and deployed an online registry: [Fox Trial Finder](#). The platform allows potential participants to easily search for relevant recruiting studies and to connect with a study team — promoting transparency and speeding recruitment.

MJFF requires all funded human studies be posted to [clinicaltrials.gov](#) and to Fox Trial Finder. That standard is reflected in our funding agreements as are requirements of monthly recruitment updates reported to MJFF staff and of a final outcome report, which we upload to our webpage of [Funded Studies](#). We require publication of results from Foundation-funded studies following completion, and we fund Open Access fees for grantees. We also frequently report out to our community on study outcomes through multiple methods such as [blog posts](#), [publications](#), [webinars](#) and [podcasts](#).

While we feel confident in our strategies to meet, and that have led in, the important evolution of research transparency, we accept that we can be more public with these requirements. Our website primarily caters to an audience of people with Parkinson's and their loved ones. As such, we leave specifics of our funding to our private agreements. We plan to pursue how we can elevate these standards to a more public forum for sharing and, perhaps, adoption by others.

To answer your included questions:

1. Has our team overlooked any relevant items, links or documents?

*In complement to the links shared above, we have attached a template clinical research funding contract, which stipulates provisions to promote transparency.*

2. Does our team's scoring of any individual item award a score that your foundation considers too low or otherwise misguided?

*We would contend the ratings for items listed on lines 6, 16, 17 and 18 do not reflect the practices of our Foundation. Requirements that support these actions are evidenced in our grant contract template.*

3. Is your foundation planning to introduce any new or additional policies or monitoring systems that are salient to this assessment?

*We plan to assess our strategy for sharing our transparency requirements publicly.*

As a research funding organization, MJFF promotes transparency through our own actions and provisions in our research contracts while remaining committed to advancing the most promising science that will make a difference in the lives of millions of people living with and at risk of brain disease. We welcome continued discussion of how various stakeholders can work together toward these common goals.

Thank you,

[REDACTED]

[REDACTED]

The Michael J. Fox Foundation for Parkinson's Research